对患有复发或难治性T细胞非霍奇金淋巴瘤的参与者的KK2223的首次人类研究
第1阶段,多中心,开放标签,非随机化,剂量 - 逐步淘汰和回填研究,在患有复发或难治性T-cell非Hodgkin淋巴瘤的参与者中
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
研究概览
详细说明
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Kyowa Kirin, Inc.
- 电话号码:+1-609-919-1100
- 邮箱:KKD.Clinical.82@kyowakirin.com
学习地点
-
-
-
Bergamo、意大利、24127
- 尚未招聘
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
首席研究员:
- Giuseppe Gritti
-
接触:
- Giuseppe Gritti
- 电话号码:39035269492
- 邮箱:giuseppe_gritti@yahoo.it
-
Bologna、意大利、40138
- 尚未招聘
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
接触:
- Luigi Zinzani Pier
- 电话号码:390516363680
- 邮箱:pierluigi.zinzani@unibo.it
-
首席研究员:
- Luigi Zinzani Pier
-
Torino、意大利、10126
- 尚未招聘
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
接触:
- Federica Cavallo
- 电话号码:390116334264
- 邮箱:f.cavallo@unito.it
-
首席研究员:
- Federica Cavallo
-
-
Torino
-
Candiolo、Torino、意大利、10060
- 尚未招聘
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
首席研究员:
- Umberto Vitolo
-
接触:
- Umberto Vitolo
- 电话号码:390116335934
- 邮箱:umberto.vitolo@ircc.it
-
-
-
-
California
-
Duarte、California、美国、91010
- 尚未招聘
- City of Hope
-
首席研究员:
- Christina Poh
-
接触:
- Christina Poh
- 电话号码:916-734-7131
- 邮箱:cpoh@coh.org
-
Orange、California、美国、92868
- 尚未招聘
- University of California, Irvine Medical Center - Hematology/Oncology
-
接触:
- Lauren Pinter Brown
- 电话号码:7144568200
- 邮箱:lpinterb@uci.edu
-
首席研究员:
- Lauren Pinter Brown
-
Stanford、California、美国、94305
- 招聘中
- Stanford University School of Medicine
-
首席研究员:
- Youn Kim
-
接触:
- Youn Kim
- 电话号码:650-723-7893
- 邮箱:younkim@stanford.edu
-
-
Florida
-
Tampa、Florida、美国、33612
- 尚未招聘
- Moffit Cancer Center
-
接触:
- Yumeng Zhang
- 电话号码:844-304-8636
- 邮箱:yumeng.zhang@moffitt.org
-
首席研究员:
- Yumeng Zhang
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 尚未招聘
- Emory University Medical Center
-
首席研究员:
- Pamela Allen
-
接触:
- Pamela Allen
- 电话号码:404-778-2407
- 邮箱:pallen5@emory.edu
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- 尚未招聘
- University of Iowa Health
-
首席研究员:
- Eric Mou
-
接触:
- Eric Mou
- 电话号码:800-777-8442
- 邮箱:eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 尚未招聘
- Beth Israel Deaconess Medical Center - Research
-
接触:
- Salvia Jain
- 电话号码:617-726-2000
- 邮箱:salvia.jain@mgh.harvard.edu
-
首席研究员:
- Salvia Jain
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine - Oncology Hospital - Public
-
首席研究员:
- Neha Mehta Shah
-
接触:
- Neha Mehta Shah
- 电话号码:314.273-8566
- 邮箱:mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601-2105
- 尚未招聘
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
首席研究员:
- Tatyana Feldman
-
接触:
- Tatyana Feldman
- 电话号码:551-996-5900
- 邮箱:tatyana.feldman@hmhn.org
-
-
New York
-
New York、New York、美国、10021-6007
- 招聘中
- Memorial Sloan Kettering Cancer Center
-
首席研究员:
- Jasmine Zain
-
接触:
- Jasmine Zain
- 电话号码:212-639-3045
- 邮箱:zainj1@mskcc.org
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- 尚未招聘
- University Hospitals Cleveland Medical Center
-
接触:
- Kevin Cooper
- 电话号码:216-844-8200
- 邮箱:kevin.cooper@uhhospitals.org
-
首席研究员:
- Kevin Cooper
-
-
Oregon
-
Portland、Oregon、美国、97239
- 尚未招聘
- Oregon Health & Science University
-
接触:
- Craig Okada
- 电话号码:503-494-8397
- 邮箱:okadac@ohsu.edu
-
首席研究员:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 尚未招聘
- University of Pennsylvania - Abramson Cancer Center
-
首席研究员:
- Stefan Barta
-
接触:
- Stefan Barta
- 电话号码:215-728-2674
- 邮箱:Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- The University of Texas - MD Anderson Cancer Center
-
首席研究员:
- Ranjit Nair
-
接触:
- Ranjit Nair
- 电话号码:171-379-2860
- 邮箱:rnair@mdanderson.org
-
-
-
-
-
Madrid、西班牙、28027
- 尚未招聘
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
接触:
- Miguel Canales Albendea
- 电话号码:34917277116
- 邮箱:macanales@unav.es
-
首席研究员:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona、Barcelona、西班牙、8036
- 尚未招聘
- Hospital Clinic De Barcelona - Hematología
-
首席研究员:
- Pablo Mozas
-
接触:
- Pablo Mozas
- 电话号码:34 93 227 22 71
- 邮箱:mozas@clinic.cat
-
L'Hospitalet de Llobregat、Barcelona、西班牙、8907
- 尚未招聘
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
首席研究员:
- Eva Domingo Domenech
-
接触:
- Eva Domingo Domenech
- 电话号码:34932607822
- 邮箱:edomingo@iconcologia.net
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- 尚未招聘
- Clinica Universidad de Navarra - Hematología
-
接触:
- Miguel Canales Albendea
- 电话号码:34917277116
- 邮箱:macanales@unav.es
-
首席研究员:
- Miguel Canales Albendea
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
实验性的:Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
大体时间:Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
大体时间:Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
大体时间:Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
大体时间:Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
大体时间:Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
大体时间:Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
大体时间:Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Blood Drug Concentration
大体时间:Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
大体时间:Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
大体时间:Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
大体时间:Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
大体时间:Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
大体时间:Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
大体时间:Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
大体时间:Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
大体时间:Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
大体时间:Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
大体时间:Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
大体时间:Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
大体时间:Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2223-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.